Search Within

Sujana Movva

Formats
  1. Meeting Abstract (26)
  2. Journal Article (21)
  3. Correspondence (1)
Groups
  1. Department of Medicine (48)
  2. Sarcoma Service (48)
  3. Solid Tumor Oncology Division (48)
  4. GSK Faculty (38)
  5. Tow Center for Developmental Oncology (TCDO) (38)
  6. Hematologic Malignancies, Division of (36)

More Groups

People
  1. Ciara Kelly (38)
  2. Sandra D'Angelo (36)
  3. William Tap (36)
  4. Mark Dickson (35)
  5. Mary Keohan (35)
  6. Ping Chi (35)

More People

Years
  1. 2025 (2)
  2. 2024 (13)
  3. 2023 (9)
  4. 2022 (14)
  5. 2021 (2)
  6. 2020 (7)

More Years

Publications
  1. Journal of Clinical Oncology (19)
  2. Clinical Cancer Research (11)
  3. Annals of Oncology (5)
  4. JCO Precision Oncology (2)
  5. Journal for ImmunoTherapy of Cancer (2)
  6. Nature Communications (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (21)
  2. American Association for Cancer Research (12)
  3. Oxford University Press (6)
  4. Biomed Central Ltd (2)
  5. Nature Publishing Group (2)
  6. American Medical Association (1)

More Publishers

Results (48)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • TTI-621-03: A phase I/II study of TTI-621 in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma (LMS)
    Meeting Abstract

    Chawla, S. P.; Kelly, C. M.; Gordon, E. M.; Quon, D. V.; Moradkhani, A.; Chua-Alcala, V. S.; Thompson, T. M.; Scheuber, A.; Bruns, I.; Allgood, V. E.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets
    Journal Article

    Nacev, B. A.; Sanchez-Vega, F.; Smith, S. A.; Antonescu, C. R.; Rosenbaum, E.; Shi, H.; Tang, C.; Socci, N. D.; Rana, S.; Zehir, A.; more...
    Nature Communications (2022)

    Fulltext@MSK | Save
  • Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma
    Journal Article

    D'Angelo, S. P.; Richards, A. L.; Conley, A. P.; Woo, H. J.; Dickson, M. A.; Gounder, M.; Kelly, C.; Keohan, M. L.; Movva, S.; Thornton, K.; more...
    Nature Communications (2022)

    Fulltext@MSK | Save
  • Interpreting nonrandomized clinical trial data in low-grade sarcoma: Differentiating clinical benefit from indolent disease is key
    Correspondence

    Rosenbaum, E.; Movva, S.; Kelly, C.
    JCO Precision Oncology (2022)

    Fulltext@MSK | Save
  • Phase Ib trial of the combination of imatinib and binimetinib in patients with advanced gastrointestinal stromal tumors
    Journal Article

    Chi, P.; Qin, L.; Camacho, N.; Kelly, C. M.; D'Angelo, S. P.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Movva, S.; Nacev, B. A.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center
    Journal Article

    Rosenbaum, E.; Antonescu, C. R.; Smith, S.; Bradic, M.; Kashani, D.; Richards, A. L.; Donoghue, M.; Kelly, C. M.; Nacev, B.; Chan, J. E.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Phase II trial of imatinib plus binimetinib in patients with treatment-naive advanced gastrointestinal stromal tumor
    Journal Article

    Chi, P.; Qin, L. X.; Nguyen, B.; Kelly, C. M.; D'Angelo, S. P.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Movva, S.; Nacev, B. A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Long-term follow-up and patterns of response, progression, and hyperprogression in patients after PD-1 blockade in advanced sarcoma
    Journal Article

    Klemen, N. D.; Hwang, S.; Bradic, M.; Rosenbaum, E.; Dickson, M. A.; Gounder, M. M.; Kelly, C. M.; Keohan, M. L.; Movva, S.; Thornton, K. A.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • A phase 1b study of avelumab plus DCC-3014, a potent and selective inhibitor of colony stimulating factor 1 receptor (CSF1R), in patients with advanced high-grade sarcoma
    Meeting Abstract

    Rosenbaum, E.; Movva, S.; Kelly, C. M.; Dickson, M. A.; Keohan, M. L.; Gounder, M. M.; Thornton, K. A.; Chi, P.; Chan, J. E.; Nacev, B.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Biomarkers of response and hyperprogression in patients with sarcoma treated with checkpoint blockade
    Meeting Abstract

    Klemen, N. D.; Hwang, S.; Bradic, M.; Rosenbaum, E.; Dickson, M.; Gounder, M.; Kelly, C. M.; Keohan, M. L.; Movva, S.; Thornton, K.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save